Related Experiment Video
Updated: Jun 25, 2025
10:16
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
7.6K
Synchronized Codelivery of Combination Chemotherapies Intratumorally Using a Lipidic Lyotropic Liquid Crystal System.
Ravi Saklani1,2, Pavan K Yadav1,2, Amrendra K Tiwari1,2
1Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow 226031, India.
ACS Applied Materials & Interfaces
|May 23, 2024
Summary
This study developed an injectable lipid liquid crystal system for synchronized intratumoral chemotherapy delivery. This novel approach enhances antitumor efficacy and reduces side effects compared to conventional methods.
Area of Science:
- Biomedical Engineering
- Materials Science
- Nanotechnology
Background:
- Combination chemotherapy offers synergistic effects but faces challenges in drug delivery and synchronization.
- Intratumoral delivery can enhance local drug concentration and reduce systemic toxicity.
- Developing stable, injectable systems for codelivering multiple drugs at precise ratios is crucial.
Purpose of the Study:
- To develop an injectable, in situ depot-forming lipidic lyotropic liquid crystal (L3C) system for synchronized intratumoral codelivery of chemotherapeutics.
- To demonstrate the feasibility of co-encapsulating hydrophilic and hydrophobic drugs within the L3C system.
- To evaluate the in vivo antitumor efficacy and toxicity of the synchronized combination chemotherapy delivered via the L3C system.
Main Methods:
- Formulation of an L3C system using amphiphilic lipids and surfactants.
- In vitro design and optimization of a synchronized chemotherapy regimen using doxorubicin (hydrophilic) and paclitaxel (hydrophobic).
- In vivo evaluation of the drug-loaded L3C system in a 4T1 breast tumor mouse model, assessing antitumor activity and cardiotoxicity.
Main Results:
- The L3C system successfully co-encapsulated both hydrophilic and hydrophobic drugs.
- The injectable L3C formulation transformed into a hexagonal mesophase depot upon intratumoral injection, enabling sustained drug release for over a month.
- Synchronized intratumoral delivery via L3C significantly enhanced antitumor efficacy and reduced cardiotoxicity compared to unsynchronized or intravenous administration.
Conclusions:
- The developed L3C system provides a promising platform for synchronized intratumoral codelivery of combination chemotherapy.
- This approach improves therapeutic outcomes by maintaining precise drug ratios at the tumor site.
- The L3C system holds potential for advancing combination cancer therapy with enhanced efficacy and safety.
